MBMarkus Bangerter

Markus Bangerter

*This is an algorithmically generated author record based on publicly available information.

Markus Bangerter has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial

    by Clemens Giessen, Ludwig Fischer von Weikersthal, Axel Hinke, Sebastian Stintzing, Frank Kullmann, Ursula Vehling-Kaiser, Julia Mayerle, Markus Bangerter, Claudio Denzlinger, Markus Sieber, et al.

    Background: Several randomized trials have indicated that combination chemotherapy applied in metastatic colorectal cancer (mCRC) does not significantly improve overall survival when compared to the sequential use of cytotoxic agents (CAIRO, MRC Focus, FFCD 2000-05). The present study investigates the question whether this statement holds true also for bevacizumab-based first-line treatment including escalation- and de-escalation strategies. Methods/Design: The AIO KRK 0110/ML22011 trial is a two-arm, multicenter, open-label randomized phase III trial comparing the efficacy and safety of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in the first-line treatment of metastatic colorectal cancer. Patients with unresectable metastatic colorectal cancer, Eastern Cooperative Oncology Group (ECOG) performance status 0-1, will be assigned in a 1:1 ratio to receive either capecitabine 1250 mg/m2 bid for 14d (d1-14) plus bevacizumab 7.5 mg/kg (d1) q3w (Arm A) or capecitabine 800 mg/m2 BID for 14d (d1-14), irinotecan 200 mg/m2 (d1) and bevacizumab 7.5 mg/kg (d1) q3w (Arm B). Patients included into this trial are required to consent to the analysis of tumour tissue and blood for translational investigations. In Arm A, treatment escalation from Cape-Bev to CAPIRI-Bev is recommended in case of progressive disease (PD). In Arm B, de-escalation from CAPIRI-Bev to Cape-Bev is possible after 6 months of treatment or in case of irinotecan-associated toxicity. Re-escalation to CAPIRI-Bev after PD is possible. The primary endpoint is time to failure of strategy (TFS). Secondary endpoints are overall response rate (ORR), overall survival, progression-free survival, safety and quality of life. Conclusion: The AIO KRK 0110 trial is designed for patients with disseminated, but asymptomatic mCRC who are not potential candidates for surgical resection of metastasis. Two bevacizumab-based strategies are compared: one starting as single-agent chemotherapy (Cape-Bev) allowing escalation to CAPIRI-Bev and another starting with combination chemotherapy (CAPIRI-Bev) and allowing de-escalation to Cape-Bev and subsequent re-escalation if necessary. Trial Registration: ClinicalTrials.gov Identifier NCT01249638 EudraCT-No.: 2009-013099-38


    • 26 November 2009
      • Vol. 151  (48) , 31-5; quiz 36

    [Anemia: from symptoms to diagnosis and therapy].

    by Bernhard Heinrich, I Schrembs, O Brudler, M Bangerter

  • Cytomorphologic Pitfall of Primary Malignant Melanoma of the Parotid Gland

    by Markus Bangerter

    Fine needle aspiration cytology (FNAC) of the salivary glands is a routine procedure in the diagnostic workup of benign and malignant lesions. Primary malignant melanoma of the salivary gland is a rare disease, and only afew cases describing FNAC have been reported. We present a case of primary malignant melanoma of the right parotid gland. Cytomorphologically it was classified as adenocarrinoma. However, histologic examination revealed the diagnosis of malignant melanoma. At first clinical presentation of the patient, no other sites were involved. It was remarkable that 3 months after diagnosis of primary malignant melanoma in the right parotid gland, supraclavicular lymph nodes appeared on the left side. The patient underwent parotidectomy and neck dissection of both sites. The cellular aspirates from primary malignant melanoma of the parotid gland were cytologically mistaken for adenocarcinoma. This cytologic pitfall required additional histologic examination.


    • 4 December 2008
      • Vol. 150, 37-8, 40

    [EGFR (epidermal growth factor receptor) inhibitor-associated skin disorders in tumor therapy].

    by G Reimer, O Brudler, B Heinrich, M Bangerter

  • Open or Closed Nuclear Membrane?

    by Markus Bangerter, Olaf Brudler, Bernhard Heinrich, Ingrid Schrembs, Martin Griesshammer

    To describe a cytomorphologic criterion that may help improve diagnostic safety in morphologic differentiation of non-Hodgkin's lymphoma (NHL) from carcinoma or sarcoma and investigate the significance of this cytomorphologic phenomenon. Eighty-two smears of NHL, carcinoma and sarcoma smears were examined. Forty-five smears were from patients with carcinoma and 35 from patients with NHL. The remaining 2 smears were from patients with sarcoma. In 40 of 46 smears of carcinoma or sarcoma the nuclear membrane was assessed as "open" by the observer. In 6 smears the membrane was assessed as "closed. " In 30 of 35 smears with histologically confirmed NHL, the membrane was estimated as being closed. In the remaining 5 smears it was assessed as open. The sensitivity of evaluating the parameter as open or closed membrane was 87% and the specificity was 86%. The negative predictive value was 89%, and the positive predictive value was 83%. We suggest that the presence of an open or closed nuclear membrane may be helpful in differentiation of malignant lymphoma from carcinoma or sarcoma and may help improve diagnostic safety in daily practice.

  • Fine Needle Aspiration Cytology and Flow Cytometry in the Diagnosis and Subclassification of Non-Hodgkin’s Lymphoma Based on the World Health Organization Classification

    by Markus Bangerter, Olaf Brudler, Bernhard Heinrich, Martin Griesshammer

    To determine the usefulness of fine needle aspiration cytology (FNAC) in combination with flow cytometry on the new World Health Organization (WHO) classification of malignant lymphoma. Smears and flow cytometry reports of patients who underwent both methods at the same time were independently examined. Both methods were classified according to the new WHO classification of malignant lymphoma. A group of 131 smears were examined. In 89 cases exact diagnosis was made by cytomorphology. Twenty-five cases were not classified exactly or were classified incorrectly, resulting in a sensitivity of 96.4% and a specificity of 85%. With flow cytometry, only 30 of 131 patients could be classified exactly, resulting in a sensitivity of 27% and specificity of 100%, respectively. The combination of methods showed a sensitivity of 85% and specificity of 100%. The combination of FNAC and flow cytometry obtained by FNAC can distinguish between benign and malignant lymphoid infiltrates and support a diagnosis of lymphoma.


    • 30 September 2004
      • Vol. 146  (40) , 30-2

    [Medical treatment of cancer in the elderly].

    by M Bangerter, B Heinrich, O Brudler

    Paralleling increasing life expectancy, the number of cases of cancer in our population is also on the increase. The question as to whether chemotherapy for the treatment of a tumor in the elderly is appropriate or not, and if so what doses are required, depends in particular on the potentially increased toxicity of the drug in the old patient. The consequence is that alternative substances may have to be sought. When planning treatment, however, additional factors have to be taken into account, such as the possibility of differences in the physiology of the tumor in the elderly, the general state of health of the patient, the presence of concomitant diseases, possible interactions with other medications, and the patient's social environment.

  • Usefulness of FDG-PET in diagnosing primary lymphoma of the liver.

    by M Bangerter, F Moog, M Griesshammer, E Merkle, M Hafner, V Ellenrieder, S N Reske, H Heimpel

    This case report shows for the first time the usefulness of positron emission tomography (PET) with 2-[18F]-fluoro-2-deoxy-D-glucose (FDG) in the diagnosis of primary non Hodgkin's lymphoma of the liver. Results of FDG-PET, which in contrast to other imaging techniques offers the advantage of screening the whole body, demonstrated a high glycolytic activity of a solitary mass in the liver with central necrosis (loss of glycolytic activity), but no spread of lymphoma to the body. These results were confirmed by ultrasound, computed tomography, magnetic resonance imaging and were biopsy proven. From our findings we conclude that in patients with liver masses with high uptake of FDG, lack of liver dysfunction and absence of signs indicating other malignancies, a primary lymphoma of the liver should be considered as a possible diagnosis.